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Summary 
Plasma Beta-endorphin (B-END) immuno- 
reactivity was measured in 19 men, 16 women at 
midcycle, and ten pregnant women at various points 
in their pregnancies. There is a significant 
difference between the levels measured in males 
and females (t = 3.74, df = 31, p = .0007). 
Pregnant women demonstrated a steady increase in 
plasma Beta-End-like immunoreactivity between 
second and third trimester and through labor. The 
levels dropped rapidly postpartum. The material 
being measured is predominantly B-end-sized. 
Psychological studies indicate that these changes 
are not strongly correlated with pain perception 
or self-reported anxiety levels. 
Beta-endorphin (B-END) is thought to be involved in the 
mediation of pain perception in animals and man. Several groups 
have shown that plasma B-END-like immunoreactivity is elevated 
during pregnancy and labor (1,2,3,4). Rats demonstrated higher 
pain thresholds as pregnancy progressed and parturition neared 
(5). Therefore the increases in endogenous opiates noted during 
pregnancy may be reflective of the body's response to pain. 
However, B-END/B-LPH and ACTH are co-produced and co-released by 
the anterior pituitary into the peripheral blood in response to 
stress among other things. Therefore, it may be suggested that 
elevated B-END-like immunoreactivity is reflective of the stress 
of pregnancy and labor or may be caused by endocrine changes not 
closely coupled to pain. We have therefore begun a series of 
experiments to: a) study changes in B-END immunoreactivity in 
normal males, females, and in pregnancy, labor and postpartum; b) 
characterize the immunoreactivity chromatographically and by 
specific antisera to determine the size, acetylation and opiate 
activity; and c) examine any possible correlations between 
B-END-like levels and perceived pain or anxiety during pregnancy 
and labor. 
METHODS 
We have developed a very sensitive radioimmunoassay to 
measure B-END-like immunoreactivity in extracted human plasma (6). 
The IC50 of the assay using antisera Brenda at 1:40,000 final 
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concentration is 10.25 fm per assay tube. The extraction 
procedure uses th~o~ep-Pak CI~ cartridge (Waters Associates, Inc). 
The recovery of [~JI] Bh-ENDVis 90%. We have determined that the 
addition of plasma extract stripped of B-END-like immunoreactivity 
by affinity purification caused the IC5^ of the standard curve to 
shift to 9.25 fm per assay tube, a 10% ~hift to the left. To 
determine the molecular size of the material being measured, we 
used a 1.5 cm X 90cm Sephadex G-50 superfine column with a 1% 
formic acid buffer (7). 
Anxiety was measured by the Spielberger State Anxiety 
Inventory (8). Pain perception was measured by a visual analog 
scale• All subjects were asked to complete both tools just prior 
to the collection of the blood samples. Blood was collected by 
venopuncture in non-laboring subjects• Laboring subjects had a 
heparin lock inserted upon admission to the labor room and all 
samples were collected from it. Blood was collected in chilled 
EDTA Vacutainers (Brand, BD). It was immediately placed on ice 
and centrifuged for I0 minutes at 4°C. serum was pipetted into 
plastic vials containing i00 microliters of 1N HCl per ml of 
serum. The sample was quickly frozen on dry ice and stored at 
-80°C until it was assayed• 
RESULTS 
Plasma samples were collected from 19 male volunteers and 14 
females at midcycle. These two groups represented control groups. 
We found that there is a significant difference between the 
B-END-like immunoreactivity of these two groups (t = 3.74, df = 
31, p = .0007). Five women were studied longitudinally throughout 
their pregnancies. We found that B-END-like immunoreac tivity 
increased steadily throughout pregnancy (Tau B = .40, N = 23, p = 
.008). Six other women were studied during labor and at term. In 
early labor, B-END-like immunoreactivity dipped slightly, but by 
the last stage of labor B-END-like immunoreactivity rose to the 
highest level. Then 24 to 48 hours postpartum there was a 
dramatic and significant (t = 3.23, d.f. = Ii, p = .008) drop in 
B-END-like immunoreac%iv ity to levels comparable to women at 
midcycle (see Table I). Although chromatographic studies of the 
plasma from pregnant women indicated that the majority of the 
material measured was B-END size, there was only a weak 
(non-significant) correlation between pain perception and 
B-END-like immunoreactivity. The same is true of self-reported 
anxiety levels. 
TABLE I 
Summary of Plasma B-End-like Immunoreactivity by Group 
N Plasma B-End(fm/ml) + S.E.M. 
Male 19 6.8 
Female ( Midcycl e) 14 2.4 
Pregnant Term 7 7.1 
Stage I Labor (0-4cm) 3 5.6 
Stage II (5-8cm) 4 6.7 
Stage III (9-10cm) 5 8.8 
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CONCLUSIONS 
We have shown that B-END-like immunoreactiv it y can be 
measured in human serum and that changes in experimental 
conditions can be detected. %qe have not demonstrated any strong 
correlations between B-END-like immunoreactivity and self-reported 
anxiety levels or pain levels. However, the number of subjects 
studied thus far is small and there is a wide range of variance 
among them. As additional individuals are studied, we will be 
able to use more powerful statistical approaches which may help to 
solve the problem of non-homogeneity of variance. 
The finding that the greatest proportion of B-END-like 
immunoreactivity in the serum of pregnant women is B-END size is 
important. The amount of B-END produced by the anterior pituitary 
is usually small compared to the amount of B-LPH produced. The 
molar ratio of B-LPH to B-END is usually 6:1. During pregnancy 
the molar ratio changes to 1:6. So, not only is the absolute 
amount of B-END-like immunoreactivity elevated, there is also a 
change in the final product. It is not clear if this change is 
reflective of alterations in the usual biosynthetic pathways in 
the anterior pituitary or if a novel source such as intermediate 
pituitary or fetus develops. Since the intermediate lobe of the 
pituitary processes POMC differently than the anterior lobe 
producing primarily N-acetylated forms of B-END studies on the 
state of acetylation of B-END in pregnancy should be revealing. 
Such studies are currently ongoing. 
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